HER-2 NEGATIVE BREAST CANCER MARKET ANALYSIS

HER-2 Negative Breast Cancer MarketSize and Trends

The global HER-2 negative breast cancer market was valued at US$ 12,647.0 Mn in 2022 and is forecast to reach a value of US$ 27,201.2 Mn by 2030 at a CAGR of 10.1% between 2023 and 2030. The global HER-2 negative breast cancer market is experiencing strong growth due to the rise in burden of breast cancer and increase in number of clinical trials across the globe. Moreover, rise in demand for safe & effective treatment and rise in focus on the development of novel drugs or therapies is expected to boost the growth of the market. However, factors such as high cost of treatment and lack of awareness among people are expected to hamper the market growth.

Global HER-2 Negative Breast Cancer Market Trends:

High demand for chemotherapy drugs is a recent trend

Chemotherapy is the most common and aggressive form of drug therapy that is used to destroy cancer cells in the body and prevent them from further dividing and growing. Chemotherapy drugs travel through the bloodstream and damage cancer cells throughout the body and have a high effect on cancer cells. Several chemotherapy drugs are used to treat HER2-negative breast cancer, either alone or in combination with other drugs. This trend is expected continue over the forecast period, driving the HER-2 negative breast cancer market growth.

Increase in research and development (R&D) is another trend

Players in the market are involved in various research and development (R&D) activities for the development of novel drugs and therapies for the treatment of HER-2 negative breast cancer. With the growing research and development activities, the pipeline products and product approvals are increasing by the market players, which in turn is expected have a positive impact on the market. This trend is also expected continue over the forecast period.